Lilly is opening up its proprietary AI models to biotech companies that want to use them to jumpstart their science.

Tal Melenboim, the visionary behind VFR.ai and StyleTech.ai, champions the cause of high-quality data as the cornerstone of ...

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research ...

Even as large language models have been making a splash with ChatGPT and its competitors, another incoming AI wave has been quietly emerging: large database models.

Chronic kidney disease (CKD) is a complex condition marked by a gradual decline in kidney function, which can ultimately ...

Cisco Systems and Splunk launched the Cisco Data Fabric at Splunk .conf25, based on Splunk’s machine data platform, for AI ...

The 2025 Bioprocessing Summit revealed knowledge gaps and changing mindsets. As some companies look towards the future, ...

The private equity secondaries market has reached an inflection point where policy considerations can no longer be treated as ...

Private cloud gives firms a single-tenant environment with strict boundaries. This matters for AI because of how models ...

Lilly is offering its AI models that can help predict a drug's behavior to biotechs, in return for being able to use those ...

Cadence announced a significant expansion of its Cadence Reality Digital Twin Platform library with a digital twin of NVIDIA ...